No Data
No Data
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT)
JMP Securities Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $31
Promising Potential of Denifanstat Drives Buy Rating for Sagimet Biosciences
Institutional Investors Have a Lot Riding on Sagimet Biosciences Inc. (NASDAQ:SGMT) With 43% Ownership
Express News | Sagimet Biosciences Announces Oral Presentation at the 9TH Annual Mash-Tag 2025 Conference
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference